Terry Vance is the Chief Business Officer of BioMotiv. Prior to joining BioMotiv, Mr. Vance was the Managing Member of EGS Healthcare Capital Partners, a late-stage venture capital fund that he co-founded in 2000. Mr. Vance’s portfolio included investments in Amylin Pharmaceuticals, Cerexa Pharmaceuticals (acquired by Forest Labs), Peninsula Pharmaceuticals (acquired by JNJ), Endius Corp (acquired by Zimmer) and CytoLogix (acquired by Dako). Before starting EGS Healthcare, Mr. Vance was a founding partner in Eagle Advisors, which provided strategic advice to emerging biotech companies that included Amylin and Corixa.
As a Venture Partner of Saints Capital, Mr. Vance led the structuring and secondary purchase of a portfolio of life science companies from a leading venture capital firm, and has co-managed the portfolio since its acquisition in 2011. He serves on the boards of public company Enanta Pharmaceuticals (NASDAQ: ENTA) and private company CircuLite.
For fifteen years Mr. Vance was an investment banker at Salomon Brothers and Goldman Sachs. At Goldman Sachs, as head of Capital Markets for the Northeastern United States, Mr. Vance was an advisor to several pharmaceutical companies, including Merck, Warner-Lambert and American Cyanamid. Earlier, he managed the distribution of private equity transactions, which included Goldman’s first direct investment in a life science venture company (IGEN International).
Mr. Vance holds an AB degree from Princeton University as well as an MBA degree from Stanford University. He has been a contributing editor to Diabetes Close-Up, an industry publication focused on metabolic disease, especially diabetes and obesity.